COVID-19: Critical Care Advisory Group
In April 2020, PHARMAC convened a group of clinical experts from across New Zealand for an ad hoc Critical Care Advisory Group.
Purpose of the group
The group was needed to advise PHARMAC on the hospital medicines needed to look after people in intensive care with COVID-19.
If there were any supply issues for these medicines, we needed to know:
- what other medicines or devices could be used
- what changes to clinical practices could be made
- the best way to implement any changes (if needed).
The group could also be asked for clinical advice relating to the hospital medical devices needed to look after people in intensive care with COVID-19.
COVID-19 treatments are not in scope
COVID-19 treatments (for example anti-viral agents) are outside of the scope of this group. PHARMAC will seek advice from other clinical advice networks on these matters.
Who is in the group
We sought experts from around the country from the disciplines of:
- intensive care
- respiratory and internal medicine
- critical care pharmacy
- critical care nursing.
Members of the Critical Care Advisory Group (as at 9 April 2020)
- Prof Brian Anderson (Chair) – Auckland DHB
- Dr Andrew Brainard – Counties Manukau DHB
- Dr Andrew Stapleton – Hutt Valley DHB
- Annie Egan – Nelson Marlborough DHB
- Dr Bruce King – Nelson Marlborough DHB
- Dr Craig Carr – Southern DHB
- Dr Gillian Bishop – Auckland DHB
- Dr Greg Frazer – Canterbury DHB
- Dr Matthew Drake – Auckland DHB
- Dr Seton Henderson – Canterbury DHB
- Steve Kirby – Counties Manukau DHB
Brian Anderson and Bruce King are members of the Pharmacology and Therapeutics Advisory Committee to PHARMAC (PTAC), which provides objective advice to PHARMAC on pharmaceuticals and their benefits. Greg Frazer is a member of PHARMAC’s Respiratory Subcommittee.
Who to contact
If you have any questions about the work of this group, email email@example.com
Last updated: 7 May 2020